OTCMKTS:ONPH Oncology Pharma (ONPH) Stock Price, News & Analysis $0.0002 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.18Volume900 shsAverage Volume7,446 shsMarket Capitalization$7,732.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Oncology Pharma alerts: Email Address Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About Oncology Pharma Stock (OTCMKTS:ONPH)Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.Read More ONPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONPH Stock News HeadlinesAugust 26, 2024 | seekingalpha.comCG Oncology: Promising Data, But Looks ExpensiveAugust 24, 2024 | msn.comCancer: 'Natural, Less Toxic' Chemo Alternative May Be on HorizonSeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 19, 2024 | reuters.comBioNTech says FDA lifts partial hold on its cancer drug trialAugust 16, 2024 | markets.businessinsider.comOptimistic Outlook on Oric Pharmaceuticals’ Cancer Therapy Pipeline and Strategic PartnershipsAugust 15, 2024 | markets.businessinsider.comPanavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer MedicineAugust 15, 2024 | seekingalpha.comPredictive Oncology Inc. (POAI) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comNew vaccine against cervical cancer combines prophylactic and therapeutic activitySeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 8, 2024 | msn.comEndometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drugAugust 6, 2024 | markets.businessinsider.comNuvectis Pharma: Strong Buy Rating on Solid Financials and Promising Oncology PipelineAugust 3, 2024 | uk.investing.comOncology Pharma Inc (ONPH)August 1, 2024 | yahoo.comJapan's Otsuka Pharma to pay up to $1.1 billion to acquire Jnana TherapeuticsJuly 31, 2024 | msn.comTargeting oncogenic transcription factors to develop potential new cancer treatmentsJuly 30, 2024 | fool.comPfizer's Upgraded Oncology Segment Powers Second-Quarter GrowthJuly 29, 2024 | bizjournals.comDenver co. spent millions to make a cancer drug it can't sell, but it's growing anywayJuly 29, 2024 | msn.comPfizer Q2 Earnings Preview: Focus on oncology, obesity treatmentsJuly 26, 2024 | bizjournals.comRx plant spent millions readying cancer drug. Now it can't sell it.See More Headlines Receive ONPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Prepackaged software Sub-IndustryComputer Software Current SymbolOTCMKTS:ONPH CUSIPN/A CIKN/A Webwww.oncology-pharma.com Phone(415) 869-1038Fax858-385-8997Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares38,663,000Free Float31,704,000Market Cap$7,732.60 OptionableNot Optionable Beta-1.04 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Chuck WagnerPresident, Treasurer & ChairmanMr. George MalesekInterim Chief Executive OfficerMr. Dimitri Theofilopolous Esq.Legal CounselKey CompetitorsElys BMG GroupNASDAQ:ELYSAreti Web InnovationsOTCMKTS:AWEBKaleido BiosciencesNASDAQ:KLDOInfinite GroupOTCMKTS:IMCIKubientNASDAQ:KBNTView All Competitors ONPH Stock Analysis - Frequently Asked Questions How have ONPH shares performed this year? Oncology Pharma's stock was trading at $0.0002 at the start of the year. Since then, ONPH shares have increased by 0.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. How do I buy shares of Oncology Pharma? Shares of ONPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ONPH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncology Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncology Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.